Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The invention relates to a vial for containing a pharmaceutical product comprising - a vial body (3) including a substantially cylindrical wall (7) extending along a main axis (X), a bottom wall (8) closing the cylindrical wall (7) at the bottom end thereof and a neck portion (9) coaxially extending from the cylindrical wall (7) at the upper end thereof; and - a cap assembly (5) attached to the neck portion (9) for sealingly closing the inner volume (24) of the vial body (3). The vial body (3) further includes at the bottom end thereof a flange (33) defining a cavity (35) with a non-cylindrical shape, whereby rotation of the vial (1) about the main axis (X) is prevented when the cavity is matingly engaged by a male connecting piece. The invention is also directed to a filling system suitable for filling such vials in sterile conditions with a pharmaceutical product.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
The present disclosure relates to hMPV F protein mutants, nucleic acids or vectors encoding a hMPV F protein mutant, compositions comprising a hMPV F protein mutant or nucleic acid, and uses of the hMPV F protein mutants, nucleic acids or vectors, and compositions.
Described herein are GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
Provided herein is a compound of the Formula I:
Provided herein is a compound of the Formula I:
Provided herein is a compound of the Formula I:
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 239/90 - Oxygen atoms with acyclic radicals attached in position 2 or 3
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
7.
COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST PEPTIDES
Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing medical information in the field of heart disease; Providing information in the field of the diagnosis and treatment of heart diseases via a website
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing medical information in the field of heart disease; Providing information in the field of the diagnosis and treatment of heart diseases via a website
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of digestive disorders; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of gastrointestinal disorders; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hepatological diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of digestive disorders; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of gastrointestinal disorders; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hepatological diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of digestive disorders; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of gastrointestinal disorders; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hepatological diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
15.
ENHANCEMENT OF CD47 BLOCKADE WITH TAXANES FOR CD47+ CANCER THERAPY
The invention provides combinations of materials and methods for disease treatment, such as CD47+ cancer treatment. The combinations include a CD47 blocking agent and a taxane.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
The invention relates to benzodiazepine pyrazolo carboxamidesand pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of invention inhibit the activity RSV N-proteins and may be useful in the treatment, prevention, suppression, and amelioration of viral infections such as RSV.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of digestive disorders; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of gastrointestinal disorders; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hepatological diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations.
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of ribonucleic acid immunogenic compositions and/or vaccines comprising polynucleotide molecules preferably encoding one or more influenza antigens, such as hemagglutinin antigens, wherein the composition is frozen or lyophilized.
Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
The invention relates to benzodiazepine pyrazolo carboxamides and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of invention inhibit the activity RSV N-proteins and may be useful in the treatment, prevention, suppression, and amelioration of viral infections such as RSV.
The present invention is directed to intermediates and an efficient process for preparing nirmatrelvir (compound of Formula I) and intermediates useful in the preparation of nirmatrelvir.
The present invention is directed to intermediates and an efficient process for preparing nirmatrelvir (compound of Formula I) and intermediates useful in the preparation of nirmatrelvir.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A system and method for providing a user with information associated with a disease or a condition. The method includes receiving user data associated with the user, receiving a query from the user, wherein the query is associated with the disease or the condition, providing content associated with the disease or the condition in response to the query, wherein the content is based on the user data, wherein the content was generated by a generative machine learning model, and providing secondary services associated with the content, wherein the secondary services comprise at least one of (i) ability to purchase a product associated with the disease or the condition or (ii) scheduling for an appointment with a healthcare provider for the disease or the condition.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
Systems and methods for assisting users in managing migraines or symptoms thereof. The methods can include receiving user data, receiving migraine attack data associated with a migraine suffered by the user, receiving third-party app data associated with the user, and providing content to the user via a device associated with the user based on at least one of the user data, the migraine attack data, the third-party app data, or engagement by the user with the software application, wherein the content assists the user in managing migraines or symptoms thereof.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders, Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders, Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders, Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines.
31.
PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME
A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
The invention relates to anhydrous crystalline Form 5 of 2-methoxy-N-{4-methoxy-6-[(1H- pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Compound A) and to pharmaceutical compositions comprising anhydrous crystalline Form 5 of Compound A and methods of treatment thereof.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to a novel method of preparing ervogastat with a metal catalyst free process. The invention also relates to novel compounds, intermediates, salts, polymorphs used and prepared by this novel method. Formula (I).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
34.
CRYSTALLINE FORMS OF A MUSCARINIC M4 RECEPTOR MODULATOR AND METHODS OF TREATING DISEASES
Crystalline forms of a muscarinic M4 receptor activator, Compound A, pharmaceutical compositions and combinations comprising those crystalline forms, their use in treating diseases or disorders and methods of producing the crystalline forms. Also provided are pharmaceutical compositions comprising a core comprising Compound A or a pharmaceutically acceptable salt or hydrate thereof, and a coating comprising an opacifier.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
35.
SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
The present invention relates to a compound of the formula I
The present invention relates to a compound of the formula I
The present invention relates to a compound of the formula I
Wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 475/00 - Heterocyclic compounds containing pteridine ring systems
36.
SOLID FORMS OF 6-[4-[[3-(DIFLUOROMETHOXY)-2-PYRIDINYL]OXY]-2-METHYLPHENYL]-1,5-DIMETHYL-2,4(1H, 3H)-PYRIMIDINEDIONE, A
Solid crystalline forms of D1 agonist as-(-)-1,5-dimethyl-6-(2-methyl-4- (3-difluoromethoxy-pyridin-2-yloxy)-phenyl]-1H-pyrimidine-2, 4-dione, as well as methods of making and using the same.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
Described herein are novel compounds in an isolated or crystalline form, pharmaceutical compositions and methods for the treatment of and prevention of various disorders, in particular, skin disorders like acne.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
12344 is H or OH; and, wherein the dashed line may be present or absent, and if present, indicates a double bond Also provided are such compounds in an isolated or crystalline form, pharmaceutical compositions and methods for the treatment of and prevention of various disorders related to ACC, in particular, skin disorders like acne.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
45.
NITROGEN-CONTAINING HETEROARYL COMPOUNDS FOR THE TREATMENT OF CHRONIC DISEASES
The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression, and amelioration of disease(s) such as allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IFF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition. Formula (I): (I).
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
The disclosure provides, among other embodiments, improved bacterial capsular saccharide glycoconjugates, improved methods of producing such glycoconjugates, immunogenic compositions comprising such glycoconjugates, and uses thereof.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Described are compositions and methods for prevention of Lyme disease. Also described are methods for production of an RNA molecule comprising an open reading frame encoding a structural domain polypeptide and an open reading frame encoding an outer surface protein A (OspA) lipoprotein polypeptide, including structural domain polypeptides from an influenza neuraminidase structural domain polypeptide, a PIV5 structural domain polypeptide and a RSV- G structural domain polypeptide.
C12N 15/62 - DNA sequences coding for fusion proteins
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
48.
SOLID FORMS OF A GABAA RECEPTOR MODULATOR AND METHODS OF ITS USE
Solid crystalline forms of GABA a receptor modulator 7-ethyl-4- (4'-(ethylsulfonyl)-6-fluoro-2'-methoxy-[l, I '-bipheny l]-3-yl)-7 H- imidazo[ 4,5-c ]pyridazine, as well as methods of making and using the same. Formula (I).
The present disclosure relates to RNA molecules encoding a Neisseria meningitidis polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of meningococcal disease.
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1,G1, L1, L2, R2, R3, a, and b are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, G1, G2and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
C07C 219/24 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV) polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, cachexia, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, cachexia, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, cachexia, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use
56.
BIPHENYL AND PHENYLPYRIDINE COMPOUNDS AS INHIBITORS OF KAT2A AND/OR KAT2B
The invention relates to compounds of Formula (I): (I), and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders, and conditions such as cancers.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
57.
COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
Provided are a combination therapy comprising inavolisib, palbociclib and fulvestrant and methods of treating PIC3CA-mutant, hormone receptor positive (HR+) and HER2 negative (HER2-) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib, palbociclib and fulvestrant. The combination therapy produces a statistically significant and clinically meaningful improvement to the patient as compared to administering palbociclib and fulvestrant alone to a comparable patient.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
Technology is disclosed for a computerized system for monitoring a respiratory condition of a human subject, the system may include one or more processors, and a computer memory having computer-executable instructions stored thereon for performing operations when executed by one or more processors; where the operations comprising collecting at least one audio sample from the human subject, generating a baseline data value using the collected at least one audio sample, collecting a second audio sample from the human subject, processing the second audio sample using the generated baseline data value, constructing a machine learning classifier using the processed second audio sample, and using the constructed machine learning classifier to determine the human subject's respiratory condition.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
The invention relates to compounds of Formula (1):
The invention relates to compounds of Formula (1):
The invention relates to compounds of Formula (1):
and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders, and conditions such as cancers.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
The present disclosure relates to benzodiazepine compounds and pharmaceutically acceptable salts thereof to their use in medicine; to pharmaceutical compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzodiazepine compounds may be useful in the treatment, prevention, suppression and amelioration of RSV infections.
PFIZER HEALTHCARE IRELAND UNLIMITED COMPANY (Ireland)
Inventor
Blake-Haskins, John Andrew
Finn, Gregory Joseph
Soltantabar, Pooneh
Acosta, Jorge Castellano
Mueller, Patrick
Abstract
Provided herein are methods of treating and/or managing multiple myeloma, which comprise administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione ("Compound A"), or an enantiomer or a mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a bispecific antibody comprising a first binding part binding to B cell maturation antigen (BCMA) and a second binding part binding to cluster of differentiation 3 (CD3).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
The present disclosure provides isolated immunogenic polypeptides comprising variant coronavirus spike proteins that are variants of a native coronavirus spike protein or fragment thereof, the variant coronavirus spike proteins having one or more modifications compared to the native coronavirus spike protein that: increase adoption by a receptor binding domain (RBD) of the variant coronavirus spike protein of an up conformation; and/or decrease adoption by a RBD of the variant coronavirus spike protein of a down conformation; and/or increase expression of the variant coronavirus spike protein compared to the native coronavirus spike protein; and/or increase adoption of a prefusion conformation; and/or decrease shedding of a S1 subunit of the variant coronavirus spike protein; and/or improve localization of the variant coronavirus spike protein to a host cell membrane. The present disclosure also provides compositions comprising the isolated immunogenic polypeptides and methods of making and using such compositions.
This invention provides methods for producing homogeneous and heterogeneous adjuvant formulations comprising a liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) a saponin, and (c) a liposome composition comprising (i) at least one phospholipid selected from phosphatidylcholine (PC) and/or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), distearyl phosphatidylcholine (DSPC), dimyristoyl phosphatidylglycerol (DMPG), dipalmitoyl phosphatidylglycerol (DPPG), distearyl phosphatidylglycerol (DSPG), and a combination thereof, and (ii) cholesterol wherein the mole percent concentration of the cholesterol in the liposome composition is greater than 50% (mol/mol), and further provides the adjuvant formulations produced from said methods.
Provided are a combination therapy comprising inavolisib, palbociclib and fulvestrant and methods of treating PIC3CA-mutant, hormone receptor positive (HR+) and HER2 negative (HER2−) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib, palbociclib and fulvestrant. The combination therapy produces a statistically significant and clinically meaningful improvement to the patient as compared to administering palbociclib and fulvestrant alone to a comparable patient.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/566 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol having an oxo group in position 17, e.g. oestrone
The present disclosure relates to a digital medicine companion for patients undergoing oncology treatments. A patient may enter symptoms on a prescription software. A wearable device may passively collect other healthcare data such as biological data and/or physical activity data. The patient may therefore be monitored using the prescription software and/or wearables. Furthermore, the prescription software may be integrated with biofluid testing systems. For example, an at-home biofluid monitoring kit and/or a laboratory system may communicate with the prescription software and/or its backend server. The healthcare data collected through the monitoring and the biofluid testing may be fed into a machine learning model, which may output whether the patient is likely to develop side effects such as cytopenia. One or more alert notifications, e.g., to a clinician dashboard and/or to the prescription software, may be triggered when the machine learning model determines a higher likelihood of such side effects.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
74.
Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
The present invention relates to fermentation methods for incorporating azido groups in bacterial capsular polysaccharides. The invention also relates to capsular polysaccharides comprising azido groups obtained by said methods. The capsular polysaccharides comprising azido groups may be used for click-based conjugation with alkyne-labeled carrier to generate glycoconjugates. The polysaccharides and glycoconjugates obtained by the method may be further used for preparation of immunogenic compositions for preventing and treating infections caused by the organism.
C07H 5/04 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
Disclosed herein are novel antibodies, novel agonist peptides, and novel dual agonist peptides. Further disclosed herein are novel antibody conjugates comprising the novel antibodies, novel agonist peptides, and/or novel dual agonist peptides disclosed herein. In some embodiments, the antibodies or antibody conjugates of the invention may be used to treat metabolic diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
77.
SYNTHESIS OF 1,5-ANHYDRO-3-({5-CHLORO-4-[4-FLUORO-2-(2-HYDROXYPROPAN-2-YL)-1-(PROPAN-2-YL)-1H-BENZIMIDAZOL-6-YL]PYRIMIDIN-2-YL}AMINO)-2,3-DIDEOXY-D-THREO-PENTITOL
This disclosure relates novel methods to prepare 1,5-anhydro-3-({5-chloro-4-[4- fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2- yl}amino)-2,3-dideoxy-D-threo-pentitol, and hydrates and stereoisomers thereof, as well as intermediates, including solid forms of the intermediates, useful for the preparation of such compounds and the synthesis of said intermediates.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
Disclosed herein are antibodies, agonist peptides, and dual agonist peptides. Further disclosed herein are antibody conjugates comprising the antibodies, agonist peptides, and/or dual agonist peptides disclosed herein. In some embodiments, the antibodies or antibody conjugates of the invention may be used to treat metabolic diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical information services, namely, providing medical information on the topic of cancer; Online information services, namely, providing information on the topic of cancer.
82.
ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF
The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Described herein are 3-phenylbenzo[b]thiophene carboxylic acid and 3-phenylbenzo[b]furan carboxylic acid derivatives and uses thereof in therapy. A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3- methoxyphenyl)-1-benzothiophene-2-carboxylic acid is also disclosed. The compounds disclosed herein can be used as a branched-chain alpha keto acid dehydrogenase kinase inhibitor or a degrader to treat conditions, for example, diabetes, kidney disease, nonalcoholic steatohepatitis, and heart failure.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (USA)
Inventor
Franklin, Edward Michael
Fennell, Brian Joseph
Stack, Edwina Catherine
Mosyak, Lidia
Apgar, James Reasoner
Chabot, Jeffrey Raymond
Khor, Bernard
Mikita, Thomas Jay
Chaparro-Riggers, Javier Fernando
Abstract
Provided herein are antibodies (including antigen-binding fragments thereof) that specifically bind to MIGIS-alpha, including for example without limitation, bispecific MIGIS-alpha/CD3 antibodies, other related antibodies, related nucleic acids, uses, and associated methods thereof. The disclosure also provides processes for making, preparing, and producing antibodies disclosed herein, including antibodies that bind to one or both of MIGIS-alpha and CD3.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
85.
ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF
Benaroya Research Institute at Virginia Mason (USA)
Inventor
Franklin, Edward Michael
Fennell, Brian Joseph
Stack, Edwina Catherine
Mosyak, Lidia
Apgar, James Reasoner
Chabot, Jeffrey Raymond
Khor, Bernard
Mikita, Thomas Jay
Chaparro-Riggers, Javier Fernando
Abstract
Provided herein are antibodies (including antigen-binding fragments thereof) that specifically bind to MIGIS-α, including for example without limitation, bispecific MIGIS-α/CD3 antibodies, other related antibodies, related nucleic acids, uses, and associated methods thereof. The disclosure also provides processes for making, preparing, and producing antibodies disclosed herein, including antibodies that bind to one or both of MIGIS-α and CD3.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
86.
ORAL CONTROLLED-RELEASE MATRIX FORMULATIONS OF 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID OR A PHARMACEUTICALLY SALT THEREOF
The invention relates to an oral controlled-release matrix formulations of danuglipron or a pharmaceutically acceptable salt thereof (e.g. tris salt of danuglipron) and process of making such formulations. The present invention further relates to tablets having such formulations and methods of using these formulations and/or tablets once daily for weight management control or for treating, e.g., T2DM, obesity, or overweight.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
The invention relates to compounds and immunoconjugates of Formula (IV) and pharmaceutically acceptable salts thereof, to the use of the compounds and immunoconjugates in medicine, to compositions containing the compounds and immunoconjugates; to processes for preparing the compounds and immunoconjugates, and to intermediates used in such processes. The compounds and immunoconjugates of the invention may be useful in the treatment of cancer.
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.
97.
METHOD OF FORMING MULTI-SPECIFIC ANTIBODIES FROM HOMODIMER ANTIBODIES AND PHARMACEUTICAL PRODUCT INCLUDING MULTI-SPECIFIC ANTIBODIES THUS OBTAINED
The present invention relates an in-vitro method of forming multi-specific antibodies from first and second homodimer antibodies. The invention also relates to multi-specific antibodies produced from the method.
The invention relates to compounds of Formula (I)
The invention relates to compounds of Formula (I)
The invention relates to compounds of Formula (I)
and pharmaceutically acceptable salts thereof, wherein A, L, X, Y and p are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may modulate the activity of antigens of interest and may be useful in inducing or enhancing an immune response against diseases, disorders and conditions mediated by antigens of interest.
The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
100.
METHODS AND DOSING REGIMENS COMPRISING A CDK2 INHIBITOR FOR THE TREATMENT OF CANCER
The disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of PF-07104091, as a monotherapy or in combination with an endocrine therapy agent and/or a CDK4/6 inhibitor.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
